Brief: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
11/05/2026 13:57
May 11 (Reuters) - Inhibrx Biosciences Inc INBX.O: INHIBRX REPORTS INTERIM PHASE 2 DATA FOR INBRX-106 IN FIRST-LINE HNSCC; INITIAL RESULTS DEMONSTRATE POTENTIAL COSTIMULATORY BENEFIT OVER PD-1 MONOTHERAPY INHIBRX BIOSCIENCES INC - INBRX-106 PLUS PEMBROLIZUMAB ACHIEVES 44.0% CONFIRMED ORR VERSUS 21.4% WITH PEMBROLIZUMAB ALONE INHIBRX BIOSCIENCES INC - THREE COMPLETE RADIOGRAPHIC RESPONSES OBSERVED WITH INBRX-106 PLUS PEMBROLIZUMAB INHIBRX BIOSCIENCES INC - UP TO 15-FOLD INCREASE IN SYSTEMIC T-CELL EXPANSION WITH INBRX-106 PLUS PEMBROLIZUMAB Source text: ID:nPn8skHlwa Further company coverage: INBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibrx
See all newsInhibrx Q1 net loss narrows as R&D costs fall
Brief: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Brief: Inhibrx to host webcast presentation to provide clinical update on INBRX-106 HexAgon study in first line HNSCC
Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say
U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway